aTyr Pharma’s (LIFE) “Buy” Rating Reiterated at Oppenheimer

Oppenheimer reissued their buy rating on shares of aTyr Pharma (NASDAQ:LIFE) in a research report report published on Tuesday morning, AnalystRatings.com reports.

Several other equities research analysts also recently commented on the stock. HC Wainwright raised shares of aTyr Pharma from a neutral rating to a buy rating and set a $13.00 target price for the company in a research note on Monday, August 17th. Zacks Investment Research cut shares of aTyr Pharma from a buy rating to a hold rating in a report on Wednesday, June 24th. Finally, ValuEngine upgraded shares of aTyr Pharma from a hold rating to a buy rating in a report on Tuesday, September 1st. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. aTyr Pharma presently has a consensus rating of Buy and an average price target of $10.19.

Shares of NASDAQ:LIFE opened at $3.85 on Tuesday. aTyr Pharma has a 52 week low of $2.13 and a 52 week high of $7.62. The company has a market capitalization of $36.72 million, a PE ratio of -1.12 and a beta of 2.14. The company has a 50 day moving average price of $3.99 and a two-hundred day moving average price of $3.76.

aTyr Pharma (NASDAQ:LIFE) last issued its earnings results on Thursday, August 13th. The biotechnology company reported ($0.69) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.73) by $0.04. aTyr Pharma had a negative net margin of 190.06% and a negative return on equity of 51.92%. As a group, equities analysts forecast that aTyr Pharma will post -2.11 earnings per share for the current year.

In related news, Director John K. Clarke sold 7,260 shares of the stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $4.01, for a total transaction of $29,112.60. Following the completion of the transaction, the director now owns 7,492 shares in the company, valued at $30,042.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold 9,560 shares of company stock valued at $38,973 in the last quarter. Corporate insiders own 9.44% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in LIFE. Oppenheimer & Co. Inc. acquired a new position in aTyr Pharma during the first quarter worth $53,000. Two Sigma Advisers LP acquired a new stake in aTyr Pharma in the first quarter valued at $102,000. UBS Group AG lifted its stake in aTyr Pharma by 1,002.1% in the first quarter. UBS Group AG now owns 37,999 shares of the biotechnology company’s stock valued at $106,000 after acquiring an additional 34,551 shares during the last quarter. Two Sigma Investments LP acquired a new stake in aTyr Pharma in the first quarter valued at $180,000. Finally, Viking Global Investors LP lifted its stake in aTyr Pharma by 156.2% in the first quarter. Viking Global Investors LP now owns 587,444 shares of the biotechnology company’s stock valued at $1,645,000 after acquiring an additional 358,161 shares during the last quarter. Institutional investors and hedge funds own 58.79% of the company’s stock.

aTyr Pharma Company Profile

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its therapeutic candidate pipeline includes ATYR1923 candidate, a fusion protein comprising the immuno-modulatory domain of histidyl tRNA synthetase fused of a human antibody that is in Phase 1b/2a clinical trial for treating patients with interstitial lung diseases (ILDs), such as pulmonary sarcoidosis; and in Phase 1 clinical trial to treat chronic hypersensitivity pneumonitis and connective tissue disease ILD.

See Also: Stocks at 52 Week High

Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.